GlassScriptPhysician profile
Aamir Javaid
NPI 1386698801
$6,403.14
in general payments reported to CMS, 2019-2025
27 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $395 · 2021: $1,188 · 2022: $995 · 2023: $1,276 · 2024: $760 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.26 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,140.88 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $719.65 | 2019-2025 | Lifevest |
| Abbott Laboratories | $663.46 | 2019-2024 | Aveir |
| Medtronic, INC. | $570.32 | 2021-2025 | Corevalve Evolut R, Resolute Onyx, Symplicity G3 |
| Merck Sharp & Dohme LLC | $560.57 | 2021-2025 | Verquvo |
| Amgen INC. | $521.51 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $500.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $399.32 | 2020-2025 | Farxiga |
| Siemens Medical Solutions USA, INC. | $175.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.89 | 2020-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $137.92 | 2024-2025 | Assure Wcd |
| Terumo Medical Corporation | $135.84 | 2019 | |
| Philips North America LLC | $118.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $104.18 | 2019-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $86.95 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.42 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $50.90 | 2022-2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $48.48 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $40.74 | 2019 | |
| Amarin Pharma, INC. | $34.95 | 2020-2021 | |
| Boston Scientific Corporation | $26.10 | 2025 | Watchman Flx |
| Lilly USA, LLC | $25.78 | 2025 | Mounjaro |
| Medtronic Vascular, INC. | $25.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $25.51 | 2019 | |
| Bard Peripheral Vascular, INC. | $24.45 | 2020 | |
| Cleerly, INC. | $20.35 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Actelion Pharmaceuticals US, INC. | $18.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Javaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.